A shocking new lawsuit has lifted the veil on a heated power struggle within the US Food and Drug Administration (FDA), revealing a cache of incendiary emails that appear to show the agency's top drug official engaging in a bitter "revenge" campaign against a whistleblower who had exposed safety concerns over a popular medication. The explosive allegations come as the FDA faces mounting scrutiny over its handling of high-profile drug approvals and potential conflicts of interest among its top officials. At the center of the controversy is the agency's director of the Office of New Drugs, who is accused of orchestrating a smear campaign against a former employee who had raised red flags about the safety of a widely prescribed antidepressant. The lawsuit, which has sparked outrage among patient advocacy groups and lawmakers, threatens to further erode public trust in the FDA's ability to regulate the pharmaceutical industry.
FDA Drug Chief’s ‘Revenge’ Emails Revealed in Explosive Lawsuit Newsweek
